Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ministry of Education of the People's Republic of China, Fudan University, Fudan University Shanghai Cancer Center, Zhongshan Hospital, Ministry of Education, Chinese PLA General Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Nantong Tumor Hospital, Henan Provincial People's Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing Medical University, Sichuan University, West China Hospital of Sichuan University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Nanfang Hospital, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Nanjing Drum Tower Hospital, Anhui Provincial Hospital, Nanchang University, Second Affiliated Hospital of Nanchang University, First Affiliated Hospital Zhejiang University, Second Affiliated Hospital of Xi'an Jiaotong University, Affiliated Hospital of Jining Medical University, Xi'an Jiaotong University, Zhejiang Cancer Hospital, Huazhong University of Science and Technology, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Hunan Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Shandong Tumor Hospital, Shandong First Medical University, First Affiliated Hospital of Bengbu Medical College, Hubei Cancer Hospital, Jilin University, First Hospital of Jilin University, First Bethune Hospital of Jilin University, Peking University, Peking University Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Zhongda Hospital Southeast University, First Affiliated Hospital of Zhengzhou University, Southwest Hospital, Jiangsu Cancer Hospital